Nanexa AB has signed a significant license and option agreement with Moderna, Inc., granting Moderna the rights to utilize Nanexa’s proprietary PharmaShell drug delivery platform for its selected compounds. This agreement marks a pivotal collaboration in the biopharmaceutical sector, as it allows Moderna to explore the potential of PharmaShell technology to enhance the release profiles of its mRNA-based therapies.
Under the terms of the agreement, Nanexa will receive an upfront payment of $3 million, with the possibility of additional milestone payments totaling up to $500 million, contingent on the successful development and commercialization of products. Moderna also holds options for up to four additional compounds, which could further expand the collaboration’s scope and financial implications.
David Westberg, CEO of Nanexa, emphasized the importance of this partnership, noting the potential of PharmaShell to address critical challenges in biologic delivery. The technology, which employs atomic layer deposition for precise encapsulation, offers tailored release profiles and enhanced stability for active pharmaceutical ingredients. As Nanexa continues to forge strategic partnerships, this agreement exemplifies its innovative approach to long-acting injectables and its commitment to advancing next-generation therapies in collaboration with leading pharmaceutical companies.
Open the full market picture for your next decision →
